RHOA and neoplasm: In pre-decitabine tumor samples, expression of CTR1[8] and RhoA[9] was lower and LINE-1 methylation tended to be higher in patients who were ≤3 months versus >3 months beyond most recent prior therapy[8], and LINE-1 methylation correlated inversely with expression of CTR1[8] and RhoA[9].